Advertisement

Topics

Latest "Proteome Systems Limited" News Stories

00:45 EST 18th November 2018 | BioPortfolio

Here are the most relevant search results for "Proteome Systems Limited" found in our extensive news archives from over 250 global news sources.

More Information about Proteome Systems Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Proteome Systems Limited for you to read. Along with our medical data and news we also list Proteome Systems Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proteome Systems Limited Companies for you to search.

Showing "Proteome Systems Limited" News Articles 1–25 of 5,500+

Relevant

Thermal Protein Profiling May Offer New Insights on Antibiotic Resistance

Scientists from the European Molecular Biology Laboratory (EMBL) say they have adapted an existing technique to study the melting behavior of proteins so that it can be used for the study of bacteria. Antibiotic resistance is spreading worldwide so there is a strong need for new technologies to study bacteria, according to the researchers who published their study (“ Thermal proteome p...


Alzheimer disease pathology and the cerebrospinal fluid proteome

Altered proteome profiles have been reported in both postmortem brain tissues and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with AD pathology, amyloid pathology, and ta...

Advanced Proteome Expands Partnership with Heidelberg

Advancing this partnership is based off of the companies also announcing positive results from an animal study. The post Advanced Proteome Expands Partnership with Heidelberg appeared first on Investing News Network.


Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

Genomic atlas of the human plasma proteome

Advanced Proteome Therapeutics Advances its Technological Capability

VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs). Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a signifi...

Prospective plasma proteome changes in preterm infants with different gestational ages

Plasma proteome changes in cord blood samples from preterm infants

Genome-wide SWAp-Tag yeast libraries for proteome exploration

Advanced Proteome Therapeutics Announces Collaboration with Noria Pharmaceuticals

VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to announce the collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates. APC will test its proprietary, site-selective, linker technology with Noria’s propriet...

Advanced Proteome Therapeutics Provides Overview of Current Activities and Strategic Objectives

VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to provide an overview of current projects prior to more detailed news releases that will be disclosed shortly. Radioimmunoconjugates APC’s site-selective technology is being employed in the emergent field of radioimm...

Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals

VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and dynamic field of antibody radioisotope conjugates which is expected to have a m...

EASI-tag enables accurate multiplexed and interference-free MS2-based proteome quantification

Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) --  Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that it has closed a first tranche of a non-brokered private placement (the “Private Placement”) raising gross pr...

Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative

VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates. APC has initiated a program to create well-defined, ch...

Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma

VANCOUVER, British Columbia , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current tre...

Encoding human serine phosphopeptides in bacteria for proteome-wide identification of phosphorylation-dependent interactions

Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as Chief Executive Officer, President and Director

VANCOUVER, British Columbia, June 06, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointment of Mr. Bill Dickie as Chief Executive Officer, President and Director of the company, effective June 6, 2018. Mr. Dickie brings with him more than 30 years of exceptionally qualified experience in b...

Shank3 mutation in a mouse model of autism leads to changes in the S-nitroso-proteome and affects key proteins involved in vesicle release and synaptic function

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism responsible for palbociclib-induced senescence, we performed thermal proteome profiling of MCF7 breast can...

Automated Packaging Systems Introduces a New Line of Wide Bag Packaging Systems

STREETSBORO, Ohio, Oct. 14, 2018 /PRNewswire/ -- Automated Packaging Systems, the world leader in high-reliability bagging systems, has introduced two new Autobag® bag packaging systems Read more...

Genomic Atlas of Human Plasma Proteome Publicized

Although plasma proteins have important roles in biological processes and are the direct targets of many drugs, the genetic factors...

Substances associated with bee ferocity are discovered

(Fundação de Amparo à Pesquisa do Estado de São Paulo) Chemical compounds identified by Brazilian researchers may explain why less aggressive bees become ferocious. Study is published in Journal of Proteome Research.

protein sequencers, variable wave length, capillary electrophoresis, liquid chromatography, gene array, medical equipment

Provider of, patient-monitoring, systems, point-of-care, diagnostics, systems, clinical-information, systems, ultrasound imaging, technologies, chemical analysis, systems

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks